CRBP8:00 AMCorbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal CancerTrial StartTrial initiation Tue, Sep 29, 2026, 8:00 AM EDTGcorbuspharma.com
CRBP7:00 AMCorbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of ObesityTrial Results • Phase 1Topline data release Mon, Sep 14, 2026, 7:00 AM EDTGcorbuspharma.com
CRBP4:01 PMCorbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In ObesityResults Call • Phase 1Results call Mon, Sep 14, 2026, 8:00 AM EDTGcorbuspharma.com